Drostanolone propionate (chemically designated as $2\\alpha\\text{-methyl-5}\\alpha\\text{-androstan-17}\\beta\\text{-ol-3-one propionate}$<\/span> of $2\\alpha\\text{-methyl-dihydrotestosterone propionate}$<\/span>) is a synthetic, esterified derivative of endogenous dihydrotestosterone (DHT) belonging to the anabolic-androgenic steroid (AAS) class. Structurally, the compound is characterized by the addition of a methyl group at the carbon-2 position in the alpha orientation ($2\\alpha\\text{-methyl}$<\/span>) and the esterification of the $17\\beta\\text{-hydroxyl}$<\/span> group with propionic acid. The $2\\alpha\\text{-methyl}$<\/span> modification sterically stabilizes the 3-keto group, impeding enzymatic deactivation by skeletal muscle $3\\alpha\\text{-hydroxysteroid dehydrogenase}$<\/span> ($3\\alpha\\text{-HSD}$<\/span>), which typically metabolizes unmethylated DHT into inactive diols. Esterification at the $17\\beta$<\/span> position increases lipophilicity, extending release from intramuscular oil depots formulated in vehicles such as arachis, grapeseed, or sesame oil, alongside cosolvents like benzyl alcohol and benzyl benzoate.<\/p>\n Within the United Kingdom regulatory framework, drostanolone propionate currently holds no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). Although historically licensed in earlier decades under trade names such as Masteril for the palliative management of post-menopausal advanced mammary carcinoma, all human therapeutic authorizations in the UK and internationally have been withdrawn in favor of targeted endocrine therapeutics. Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, drostanolone propionate is categorized as a Class C, Schedule 4 (Part II) controlled drug. It is not listed in the British National Formulary (BNF) and is absent from NHS prescribing formularies. Preparations currently circulating originate almost exclusively from illicit underground laboratories (UGLs) and unregulated supply chains, presenting significant public health risks involving non-sterility, sub- or suprapotent dosing, and particulate or heavy-metal contamination.<\/p>\n The pharmacodynamics of drostanolone propionate involve selective androgen receptor activation, absence of enzymatic aromatisation, and competitive inhibition of oestrogenic signaling:<\/p>\n Androgen Receptor (AR) Agonism:<\/b> Following cleavage of the propionate ester by endogenous tissue esterases, free drostanolone binds directly to intracellular androgen receptors in skeletal muscle, bone, dermal structures, and the central nervous system. Because the $2\\alpha\\text{-methyl}$<\/span> moiety prevents rapid local muscular inactivation by $3\\alpha\\text{-HSD}$<\/span>, the ligand-receptor complex translocates into the cell nucleus, binding androgen response elements (AREs) on genomic DNA. This stimulates RNA polymerase II transcription, increasing nitrogen retention, promoting amino acid incorporation into skeletal muscle myofibrils, and producing an anabolic-to-androgenic ratio estimated at approximately $62:25$<\/span> (relative to testosterone at $100:100$<\/span>).<\/p>\n<\/li>\n Complete Resistance to Aromatase and Anti-Oestrogenic Actions:<\/b> Due to the fully saturated $5\\alpha\\text{-androstane}$<\/span> steroid nucleus, drostanolone cannot serve as a substrate for the cytochrome P450 aromatase enzyme complex ($CYP19A1$<\/span>), preventing any metabolic conversion into $17\\beta\\text{-oestradiol}$<\/span>. Furthermore, drostanolone exhibits competitive inhibition of the aromatase enzyme and functions as a partial antagonist at oestrogen receptor alpha ($ER\\alpha$<\/span>) in breast tissue, providing the pharmacological basis for its historical therapeutic role in arresting hormone-sensitive mammary neoplasia.<\/p>\n<\/li>\n Lack of $5\\alpha\\text{-Reductase}$<\/span> Amplification:<\/b> Because the molecule is already reduced at the 5-position, it does not interact with or undergo metabolic amplification by $5\\alpha\\text{-reductase}$<\/span> isoenzymes into a more active androgen; target-tissue effects are mediated directly by the parent compound.<\/p>\n<\/li>\n HPG Axis Suppression:<\/b> Through direct negative feedback at the hypothalamic arcuate nucleus and anterior pituitary gonadotrophs, drostanolone suppresses gonadotropin-releasing hormone (GnRH), luteinising hormone (LH), and follicle-stimulating hormone (FSH) release, leading to downstream shutdown of endogenous testicular testosterone production.<\/p>\n<\/li>\n<\/ul>\n Drostanolone propionate possesses no approved clinical indications in the United Kingdom. There are no active pharmaceutical preparations containing drostanolone propionate approved or marketed for human healthcare within the NHS.<\/p>\n The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate drostanolone propionate into any clinical pathway. It is absent from contemporary clinical guidelines governing breast cancer management, male hypogonadism, or sarcopenia. Modern oncological therapy relies entirely on targeted selective oestrogen receptor modulators (e.g., tamoxifen), aromatase inhibitors (e.g., anastrozole, letrozole), selective oestrogen receptor downregulators (e.g., fulvestrant), and CDK4\/6 inhibitors.<\/p>\n The practical application of drostanolone propionate is confined entirely to illicit athletic bodybuilding, physical enhancement, and competitive sports doping. In these non-medical sectors, it is utilized for:<\/p>\n Preservation of lean skeletal muscle mass during phases of severe caloric restriction (“cutting”).<\/p>\n<\/li>\n Aesthetic reduction of subcutaneous water retention and muscular definition enhancement, driven by its anti-oestrogenic and non-aromatising profile.<\/p>\n<\/li>\n Augmentation of neuromuscular efficiency and power output without significant water-weight gain.<\/p>\n<\/li>\n<\/ul>\n Drostanolone propionate holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never be substituted for evidence-based, MHRA-licensed testosterone replacement therapy (TRT).<\/p>\n Because drostanolone propionate is formulated as an oily solution intended for deep intramuscular administration, its pharmacokinetics reflect sustained depot kinetics:<\/p>\n Absorption and Depot Cleavage:<\/b> Following intramuscular injection into gluteal or vastus lateralis sites, the lipophilic steroid ester forms an intramuscular reservoir. The short propionate ester chain gradually partitions into extracellular fluids, where it is rapidly cleaved by local tissue and circulating non-specific esterases to liberate free, pharmacologically active drostanolone. Peak serum concentrations ($T_{max}$<\/span>) are achieved within 24 to 48 hours post-injection.<\/p>\n<\/li>\n Distribution:<\/b> Drostanolone circulates in systemic blood bound to serum proteins. It exhibits moderate-to-high binding affinity for sex hormone-binding globulin (SHBG) and human serum albumin. By binding to SHBG, it may competitively displace endogenous testosterone or co-administered steroids, transiently elevating the free bioactive fraction of other circulating androgens. It possesses a moderate volume of distribution ($V_d$<\/span>), distributing into adipose, muscular, and androgen-responsive tissues, and crossing the blood-brain barrier.<\/p>\n<\/li>\n Biotransformation:<\/b> Drostanolone undergoes extensive hepatic metabolism, involving reduction of the 3-keto group, oxidation of the $17\\beta\\text{-hydroxyl}$<\/span> group, and Phase II conjugation. The primary urinary metabolites identified in human excretion studies include $2\\alpha\\text{-methyl-5}\\alpha\\text{-androstan-3}\\alpha\\text{-ol-17-one}$<\/span> and its epimeric forms, which are subsequently conjugated into glucuronide and sulfate forms.<\/p>\n<\/li>\n Elimination:<\/b> Systemic elimination is predominantly renal, with more than 60\u201375% of excreted dose metabolites cleared in the urine as polar conjugates; the remainder is eliminated via biliary excretion into faeces. The effective elimination half-life ($t_{1\/2}$<\/span>) of the propionate ester depot is relatively short, averaging approximately 2 to 3 days, necessitating frequent intramuscular dosing (e.g., alternate-day administration) in illicit regimens to maintain stable serum titers. Trace conjugated metabolites remain detectable via gas chromatography-mass spectrometry (GC-MS) anti-doping screens for several weeks post-cessation.<\/p>\n<\/li>\n<\/ul>\n The primary physiological effect reported in non-medical contexts is increased muscle hardness, modest nitrogen retention, and preservation of fat-free mass under hypocaloric conditions, with an absence of peripheral oestrogenic oedema. However, its non-aromatising DHT-derivative profile produces notable multi-system adverse effects:<\/p>\n Cardiovascular Toxicity:<\/b><\/p>\n Severe atherogenic dyslipidaemia: potent hepatic lipase stimulation leads to substantial reductions in high-density lipoprotein cholesterol (HDL-C; commonly dropping below $0.4\\text{ to }0.6\\text{ mmol\/L}$<\/span>) and concomitant elevations in low-density lipoprotein cholesterol (LDL-C), accelerating arterial atherogenesis.<\/p>\n<\/li>\n Systemic hypertension: secondary to vascular endothelial stiffness and elevated peripheral resistance.<\/p>\n<\/li>\n Polycythaemia: androgen-driven stimulation of erythropoiesis can raise haematocrit ($>52\\text{–}54\\%$<\/span>), increasing blood viscosity and the risk of thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke).<\/p>\n<\/li>\n Subclinical left ventricular hypertrophy (LVH): prolonged exposure promotes pathological concentric myocardial remodeling and impaired diastolic filling.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Endocrine and Gonadal Axis Suppression:<\/b><\/p>\n Marked suppression of the HPG axis: persistent negative feedback inhibition causes severe hypogonadotrophic hypogonadism, marked testicular atrophy, oligospermia or azoospermia, and temporary or permanent erectile dysfunction\/loss of libido following cessation.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Androgenic and Dermatological Effects:<\/b><\/p>\n Marked androgenic dermatopathy: due to its direct DHT structure, drostanolone frequently induces severe nodulocystic acne (especially across the back, shoulders, and chest) and accelerated androgenetic alopecia (male pattern baldness) in individuals with genetic follicle sensitivity.<\/p>\n<\/li>\n Virilisation in Females: If administered to females, drostanolone induces profound, often irreversible virilising signs, including clitoromegaly, irreversible vocal cord deepening, hirsutism, alopecia, and severe menstrual irregularities.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Neuropsychiatric Disturbances:<\/b><\/p>\n Increased emotional volatility, aggressive irritability, insomnia, and mood dysregulation secondary to central androgen receptor hyperactivation.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Hepatic Safety Profile:<\/b><\/p>\n Unlike $17\\alpha\\text{-alkylated}$<\/span> oral steroids (e.g., oxandrolone, stanozolol), drostanolone propionate does not cause classic severe peliosis hepatis or acute cholestatic jaundice; however, chronic administration can produce mild transaminase elevations (ALT\/AST).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Given its non-approved clinical status and potent androgenic profile, drostanolone propionate requires strict adherence to pharmacological contraindications and harm-minimisation standards:<\/p>\n Contraindications:<\/b><\/p>\n Absolute Contraindication in All Humans: The substance is an unapproved, illicit chemical formulation lacking therapeutic safety approval.<\/p>\n<\/li>\n Malignancy: Absolute contraindication in prostate adenocarcinoma, male breast carcinoma, or any androgen-sensitive neoplastic disorder.<\/p>\n<\/li>\n Pre-existing Cardiovascular Disease: Absolute contraindication in severe coronary artery disease, history of myocardial infarction, chronic heart failure, or uncontrolled hypertension.<\/p>\n<\/li>\n Pregnancy and Lactation: Absolute contraindication; high teratogenic potential, causing catastrophic virilisation of female fetuses and reproductive developmental failure.<\/p>\n<\/li>\n Severe Hepatic or Renal Impairment: Contraindicated in chronic kidney disease or significant liver dysfunction.<\/p>\n<\/li>\n Paediatric Population: Contraindicated in children and adolescents due to premature epiphyseal closure and stunted adult stature.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Drug Interactions:<\/b><\/p>\n Oral Anticoagulants (e.g., Warfarin, DOACs):<\/i> Anabolic steroids enhance anticoagulant sensitivity by altering prothrombin time and hepatic clotting factor synthesis, increasing haemorrhagic risk.<\/p>\n<\/li>\n Insulin and Hypoglycaemic Agents:<\/i> Androgens improve peripheral insulin sensitivity and alter carbohydrate handling; co-administration can trigger unexpected hypoglycaemic episodes in diabetic patients.<\/p>\n<\/li>\n Other Anabolic and Stimulant Agents:<\/i> Concurrent stacking with other AAS, selective androgen receptor modulators (SARMs), or thermogenic stimulants (e.g., clenbuterol, ephedrine) synergistically magnifies cardiovascular, thrombotic, and psychiatric morbidity.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Clinical Precautions and Harm Minimisation:<\/b><\/p>\n Cardiovascular Alarm Symptoms (“Red Flags”): Patients presenting with central crushing chest pain, unexplained acute dyspnoea, sudden focal weakness\/numbness, or acute unilateral leg swelling require immediate emergency (999\/A&E) transfer.<\/p>\n<\/li>\n Comprehensive Diagnostic Workup: Clinicians encountering individuals using illicit drostanolone propionate should perform a clinical risk assessment: 12-lead ECG, blood pressure evaluation, full blood count (monitoring haematocrit), comprehensive lipid profile (total cholesterol, HDL-C, LDL-C, triglycerides), liver function tests, renal parameters (urea, electrolytes, eGFR), and an early-morning endocrine panel (total testosterone, SHBG, LH, FSH, oestradiol).<\/p>\n<\/li>\n Clinical Cessation Support: Clinicians should counsel patients directly on the health hazards of unregulated UGL steroids, support compound cessation, and refer to endocrinology services for the management of prolonged post-AAS hypogonadotrophic hypogonadism when indicated.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n 2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
\n
\n
\n
\n